Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

A 67-Old Woman with Cervical Cancer : Episode 1

Navigating Complex Cervical Cancer Cases: Therapeutic Challenges and Innovations

October 2, 2023
By Ramez N. Eskander, MD
News
Video

Ramez N. Eskander, MD, discusses a challenging cervical cancer case, highlighting treatment advances and decision-making in recurrent and metastatic settings.

Now Viewing

EP: 1.Navigating Complex Cervical Cancer Cases: Therapeutic Challenges and Innovations

EP: 2.HPV and Cervical Cancer: Prevention and Screening Strategies

EP: 3.Biomarkers in Cervical Cancer: Guiding Innovative Treatments

EP: 4.Revolutionizing Frontline Cervical Cancer Treatment: Trials to Transformative Therapies

EP: 5.Recurrent Cervical Cancer Treatment Evolution: Immunotherapy and Beyond

EP: 6.Tisotumab Vedotin: Advancing Cervical Cancer Treatment

EP: 7.Managing Treatment-Related Side Effects of Tisotumab Vedotin

EP: 8.Innovations in Cervical Cancer Treatment: Exploring Tisotumab Vedotin Combinations

Transcript:

Ramez N. Eskander, MD: Hello. My name is Ramez Eskander. I’m a gynecologic oncologist at the University of California San Diego, where I also help lead the fellowship program. It is a pleasure to be with you here today. Thank you for joining me to discuss therapeutic advances in the cervical cancer arena for this Targeted Oncology program. I‘d like to start our conversation by discussing a patient case that reflects treatment opportunities in the management of advanced-stage or recurrent cervical cancer.

In this particular scenario, a 67-year-old [woman] presented with clinical stage IIB squamous cell cervical carcinoma. Importantly, at the time of presentation, a PET/CT scan was ordered, and the results of the PET/CT were notable for 2 important things. There were FDG [18F-fluorodeoxyglucose]-avid pulmonary nodules measuring 1.5 cm in largest diameter, and there was also an enlarged FDG-avid sternoclavicular mass. In the context of these PET/CT findings, an IR [interventional radiology]-guided biopsy was recommended and completed. The IR-guided biopsy of the pulmonary mass, which was amenable to biopsy for diagnostic consideration…returned consistent with metastatic squamous cell cervical carcinoma. Importantly, the biopsy of the lung mass was compared with the primary cervical cancer biopsy, and they appeared to be consistent with metastatic primary cervical carcinoma.

Based on the fact that this patient had stage IVB disease and that she was diagnosed before the results of the KEYNOTE-826 trial, she was started on systemic chemotherapy based on GOG [Gynecologic Oncology Group] protocol 240 and received cisplatin, paclitaxel, and bevacizumab treatment. After 3 cycles of systemic therapy with cisplatin, paclitaxel, and bevacizumab, the patient had a repeat PET/CT scan, which showed a response to treatment with a reduction in the size and \ FDG uptake of the pulmonary metastatic nodule, the sternoclavicular mass, [and] the primary cervical lesion. As such, the patient [received] an additional 3 cycles of chemotherapy, and after 6 cycles of treatment, repeat radiographic imaging showed what appeared to be a complete radiographic response. Clinical exam showed resolution of her cervical cancer on palpation and visual inspection.

So we have a patient who was initially diagnosed with stage IVB disease; was subsequently treated with systemic chemotherapy with cisplatin, paclitaxel, and bevacizumab therapy; and had a clinical response and a radiographic complete response [CR]. We discussed treatment management options. The patient had a bit of a tough time with cytotoxic chemotherapy because of hematologic adverse events, so the decision was made to proceed with a maintenance bevacizumab treatment. Unfortunately, follow-up imaging after completion of cytotoxic chemotherapy and while [the patient was] on maintenance bevacizumab therapy showed evidence of new pulmonary nodules, which were concerning for metastatic disease recurrence. These were once again amenable to IR-guided biopsy. A biopsy was completed [and confirmed] metastatic disease recurrence.

At this juncture, importantly, the patient’s tissue was also examined for a PD-L1 CPS score, and her PD-L1 CPS [combined positive score] was elevated at 50. So based on the FDA approval of pembrolizumab in this patient population, this patient was started on 400 mg of pembrolizumab IV [intravenously] every 6 weeks. [She] tolerated the immunotherapy reasonably well, although unfortunately, after cycle 3 of pembrolizumab, repeat radiographic imaging once again appeared to show disease progression, and the patient developed what appeared to be immune-related hepatitis while on immune checkpoint inhibition.

So…[we have] a patient who was treated with systemic chemotherapy, developed disease recurrence after a CR, had a positive CPS score of 50, was then treated with single-agent pembrolizumab, and after 3 cycles of therapy had radiographic imaging showing disease progression. And at this point, the patient is sitting in the office and we’re talking about treatment and management options and opportunities for her…. Independent of enrollment on a clinical trial, [I was thinking,] “What standard of care options do we have?” I thought she was an excellent candidate for tisotumab vedotin, an antibody-drug conjugate as a single-agent treatment. So she was started on tisotumab vedotin and thankfully benefited. She had 9 total cycles of therapy with what appears to be a partial response followed by stable disease, and after cycles of therapy was identified to have radiographic disease progression. And so we had to transition her to an alternate treatment strategy.

Transcript is AI generated and edited for readability.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
Related Content

FDA Fast-Tracks Novel ADC in Cervical Cancer

FDA Fast-Tracks Novel ADC in Cervical Cancer

Sabrina Serani
May 9th 2025
Article

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

Read More


Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Targeted Oncology Staff
April 21st 2025
Article

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.

Read More


Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Tony Berberabe, MPH
February 11th 2025
Article

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive exploration of immunotherapy and optimal treatment sequences.

Read More


Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Targeted Oncology Staff
December 19th 2024
Article

During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.

Read More


FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

Jordyn Sava
December 5th 2024
Article

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Read More


Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Jordyn Sava
November 13th 2024
Article

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.

Read More

Related Content

FDA Fast-Tracks Novel ADC in Cervical Cancer

FDA Fast-Tracks Novel ADC in Cervical Cancer

Sabrina Serani
May 9th 2025
Article

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

Read More


Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer

Targeted Oncology Staff
April 21st 2025
Article

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.

Read More


Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer

Tony Berberabe, MPH
February 11th 2025
Article

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive exploration of immunotherapy and optimal treatment sequences.

Read More


Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer

Targeted Oncology Staff
December 19th 2024
Article

During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.

Read More


FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

FDA Grants CRB-701 Fast Track Status in R/R Cervical Cancer

Jordyn Sava
December 5th 2024
Article

CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Read More


Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors

Jordyn Sava
November 13th 2024
Article

A phase 1 trial of pembrolizumab plus denileukin diftitox shows 27% response and 33% clinical benefit in recurrent solid tumors, with manageable toxicity.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.